Mid America Clinical Laboratories, LLC

Mid America Clinical Laboratories, LLC was paid $20.40M by Medicaid between Jan 2018 and Dec 2021, across 263 billing codes. Its largest line is 87801, Infectious agent detection by nucleic acid; amplified probe, multiple organisms — 14% of everything it billed.

33Billing provider infoMID AMERICA CLINICAL LABORATORIES, LLC
INDIANAPOLIS, IN 46219

33aNPI1699734640assigned 03/20/2006

33bProvider typeClinical Medical Laboratory

28Total paid$20.40M

24GClaims1,970,080

24DCodes billed263

24AFirst – last monthJan 2018 – Dec 2021

Compared with peers

Next to other Clinical Medical Laboratory providers in Indiana

Rank by total paid#3 of 66

Median peer was paid$53K

This provider vs. median388×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	620,310	$2.72M
2019	585,977	$7.75M
2020	598,347	$7.90M
2021	165,446	$2.03M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	14%	34,347	26,976	$2.76M
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	7.6%	29,426	18,746	$1.55M
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	6.6%	68,812	57,209	$1.34M
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	6.6%	68,619	57,040	$1.34M
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	4.7%	44,007	37,057	$957K
80050	General health panel	3.8%	23,317	19,166	$778K
80061	Lipid panel	3.7%	98,916	85,438	$763K
84443	Thyroid stimulating hormone (TSH)	3.6%	78,509	67,897	$741K
80053	Comprehensive metabolic panel	3.5%	122,035	105,178	$711K
80081		2.8%	11,187	9,433	$580K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	2.6%	35,823	30,849	$530K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	2.3%	110,495	93,645	$462K

251 more codes

87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	1.9%	18,878	$386K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	1.7%	12,405	$356K
83036	Hemoglobin; glycosylated (A1C)	1.7%	64,406	$355K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	1.6%	21,313	$328K
36415	Collection of venous blood by venipuncture	1.5%	225,639	$311K
87086	Culture, bacterial; quantitative colony count, urine	1.5%	59,003	$305K
88175	Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer	1.2%	15,854	$243K
87088		1.2%	46,241	$242K
80074		1.0%	7,193	$207K
86003		<1%	3,721	$195K
83013		<1%	4,443	$192K
86803		<1%	19,677	$179K
82607		<1%	18,164	$151K
82728		<1%	17,537	$137K
84439		<1%	26,089	$137K
88142		<1%	11,456	$132K
86480		<1%	3,756	$119K
85027		<1%	29,191	$113K
82746		<1%	13,290	$111K
87081		<1%	22,138	$106K
83970		<1%	5,600	$100K
87799		<1%	3,523	$100K
80048	Basic metabolic panel (calcium, ionized)	<1%	26,783	$98K
87077		<1%	18,747	$97K
87186		<1%	17,510	$93K
83550		<1%	15,591	$78K
86235		<1%	1,969	$72K
87522	Neg quan hep c or qual rna	<1%	2,799	$72K
86592		<1%	25,116	$70K
84153		<1%	6,589	$68K
87070		<1%	12,730	$67K
83540		<1%	17,625	$66K
87536		<1%	1,851	$65K
84146		<1%	5,042	$64K
84403		<1%	4,289	$62K
87902		<1%	342	$62K
82570		<1%	22,136	$58K
86787		<1%	6,673	$57K
84702		<1%	8,977	$56K
83516		<1%	7,487	$55K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	<1%	274	$52K
86038		<1%	7,322	$52K
83001		<1%	4,288	$51K
86140		<1%	16,213	$50K
82950		<1%	14,552	$49K
82043		<1%	16,853	$49K
87340		<1%	9,035	$46K
82670		<1%	2,475	$43K
87209		<1%	2,136	$38K
86696		<1%	2,836	$38K
84144		<1%	2,714	$37K
81001		<1%	21,027	$37K
84481		<1%	3,881	$36K
82784		<1%	4,611	$35K
88174		<1%	2,132	$33K
87512		<1%	1,352	$32K
86769		<1%	1,024	$30K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	<1%	2,947	$29K
85652		<1%	17,315	$27K
88141		<1%	1,705	$26K
83735		<1%	8,091	$26K
83021		<1%	2,650	$26K
86850		<1%	6,017	$25K
83880		<1%	1,608	$25K
82785		<1%	2,123	$24K
86706		<1%	3,823	$24K
84402		<1%	1,646	$24K
87255		<1%	1,042	$22K
86160		<1%	1,784	$22K
83002		<1%	1,886	$22K
86695		<1%	2,751	$22K
80076		<1%	5,060	$22K
86200		<1%	2,679	$21K
83655		<1%	2,283	$20K
86376		<1%	2,269	$20K
87147		<1%	6,608	$20K
83690		<1%	6,052	$20K
83525		<1%	2,604	$20K
82951		<1%	2,154	$19K
87177		<1%	2,138	$19K
86665		<1%	732	$19K
85060		<1%	1,500	$18K
84425		<1%	1,439	$18K
86147		<1%	652	$17K
82274		<1%	2,340	$17K
82150		<1%	3,907	$17K
80164		<1%	2,505	$17K
83014		<1%	3,086	$16K
87075		<1%	4,003	$16K
86870		<1%	371	$15K
85240		<1%	1,481	$15K
86431		<1%	4,358	$15K
84134		<1%	3,081	$15K
80055		<1%	519	$15K
85610		<1%	6,646	$15K
87625		<1%	866	$15K
82105		<1%	1,513	$15K
86800		<1%	1,506	$14K
86334		<1%	1,447	$14K
86704		<1%	1,861	$14K
86780		<1%	1,699	$14K
86146		<1%	549	$14K
82652		<1%	760	$14K
86225		<1%	1,793	$14K
84550		<1%	5,705	$13K
86708		<1%	1,749	$13K
84480		<1%	1,971	$13K
82627		<1%	880	$13K
82533		<1%	1,493	$13K
87493		<1%	579	$13K
84703		<1%	2,288	$13K
82550		<1%	3,882	$13K
86762		<1%	1,341	$12K
82977		<1%	2,490	$11K
87427		<1%	1,454	$11K
85730		<1%	2,874	$10K
84165		<1%	2,138	$10K
87205		<1%	4,383	$10K
82248		<1%	3,798	$9K
80069		<1%	2,964	$9K
84460		<1%	3,530	$9K
84100		<1%	4,195	$9K
87045		<1%	1,464	$9K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	287	$8K
85245		<1%	619	$8K
85246		<1%	624	$8K
86039		<1%	1,100	$8K
83615		<1%	2,193	$8K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	17,553	$8K
86361		<1%	874	$8K
83721		<1%	2,117	$7K
83993		<1%	597	$7K
86255		<1%	966	$7K
85045		<1%	3,763	$7K
84450		<1%	2,714	$7K
87046		<1%	1,478	$7K
84156		<1%	3,684	$6K
86664		<1%	525	$6K
82952		<1%	2,037	$5K
82947		<1%	2,289	$5K
82465		<1%	1,748	$5K
80178		<1%	1,650	$5K
81003		<1%	3,569	$5K
83921		<1%	547	$4K
80197		<1%	954	$4K
84478		<1%	1,172	$4K
84436		<1%	1,460	$4K
86304		<1%	320	$4K
87481		<1%	1,149	$4K
84590		<1%	527	$4K
83520		<1%	1,775	$4K
82565		<1%	1,756	$4K
83090		<1%	473	$4K
82525		<1%	499	$4K
84681		<1%	278	$4K
85384		<1%	641	$4K
82677		<1%	412	$4K
86900		<1%	1,769	$3K
86901		<1%	1,729	$3K
85576		<1%	162	$3K
85379		<1%	483	$3K
82747		<1%	345	$3K
86021		<1%	587	$3K
86705		<1%	379	$3K
87510		<1%	931	$3K
87480		<1%	931	$3K
84630		<1%	776	$3K
82310		<1%	1,005	$3K
82330		<1%	498	$3K
83883		<1%	378	$3K
86618		<1%	317	$3K
86765		<1%	186	$3K
85613		<1%	417	$3K
87660		<1%	850	$3K
82542		<1%	167	$2K
85335		<1%	288	$2K
85018		<1%	1,628	$2K
86336		<1%	413	$2K
81015		<1%	1,470	$2K
84155		<1%	1,374	$2K
84270		<1%	110	$2K
87324		<1%	254	$2K
82140		<1%	226	$2K
82247		<1%	700	$2K
86812		<1%	94	$2K
85014		<1%	1,167	$2K
87149		<1%	94	$2K
86008		<1%	153	$2K
84445		<1%	53	$1K
86300		<1%	124	$1K
84075		<1%	530	$1K
84432		<1%	113	$1K
82040		<1%	520	$1K
82103		<1%	108	$1K
81513		<1%	3,796	$1K
82731		<1%	14	$1K
87517		<1%	25	$1K
86317		<1%	79	$994.58
85046		<1%	225	$923.60
86645		<1%	74	$844.11
86593		<1%	274	$782.21
85670		<1%	204	$777.63
82397		<1%	146	$753.89
85397		<1%	53	$732.23
86702		<1%	72	$730.06
87184		<1%	134	$722.58
86148		<1%	94	$642.39
85041		<1%	334	$601.87
83020		<1%	136	$589.60
84132		<1%	180	$550.02
87102		<1%	86	$482.19
85250		<1%	43	$480.02
86701		<1%	71	$479.85
82378		<1%	65	$473.46
85004		<1%	132	$471.42
86644		<1%	45	$460.44
99001		<1%	659	$426.50
82390		<1%	42	$411.04
83718		<1%	62	$406.24
86308		<1%	88	$405.23
84520		<1%	220	$398.14
85007		<1%	193	$395.82
87206		<1%	105	$378.81
81025		<1%	68	$349.21
80156		<1%	135	$328.37
85049		<1%	124	$319.74
85048		<1%	183	$280.00
82164		<1%	34	$253.41
87804	Infectious agent antigen detection by immunoassay; Influenza, each type	<1%	18	$247.52
84305		<1%	18	$245.84
80185		<1%	55	$229.95
84482		<1%	20	$219.74
84207		<1%	14	$206.58
87101		<1%	49	$174.08
80177		<1%	87	$137.88
84154		<1%	13	$136.57
36416		<1%	65	$136.33
82672		<1%	14	$136.28
87040		<1%	35	$135.83
86709		<1%	13	$120.61
87140		<1%	15	$106.56
87220		<1%	48	$91.73
80175		<1%	12	$90.90
85660		<1%	18	$85.14
G0103	Prostate cancer screening; prostate specific antigen test (psa)	<1%	1,011	$80.19
84295		<1%	12	$44.03
G0472	Hepatitis c antibody screening, for individual at high risk and other covered indication(s)	<1%	1,105	$16.18
G0145	Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision	0%	451	$0.00
81596		0%	72	$0.00
G0475	Hiv antigen/antibody, combination assay, screening	0%	31	$0.00
G0476	Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test	0%	12	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialKMETZ, THOMAS (CFO)

Same official

Other billing entities under KMETZ, THOMAS

Full network →

Provider	Location	Paid
Mid America Clinical Laboratories, LLC	Indianapolis, IN	$34K
Mid America Clinical Laboratories, LLC	Indianapolis, IN	$6K
Mid America Clinical Laboratories, LLC	Indianapolis, IN	$496.39
Mid America Clinical Laboratories, LLC	Indianapolis, IN	$163.06

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.